Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
8th grade Avg
|
New words:
accumulator, Acknowledgment, agent, altogether, Amsterdam, Anticoagulant, anticompetitive, Article, Bavencio, Besponsa, Bipartisan, blaylock, borne, Branch, build, burden, California, carcinoma, cell, CETA, cited, concurrent, concurrently, construction, content, copay, debarment, disadvantaged, divestment, exclusionary, expiry, extract, field, flexibility, forward, Geography, gouging, Harmonisation, hematology, Home, inflammatory, inherited, intensify, inter, KGaA, Lisbon, longstanding, Maryland, maternal, matter, Merck, Meridian, Merkel, met, metastatic, modestly, narrowing, neuromuscular, newer, notable, outlining, paradigm, parity, passed, pave, Pennsylvania, procurement, prostate, Protonix, Provincial, reauthorized, Remicade, repatriating, ronald, run, secondary, Senate, step, sui, suit, tanezumab, tick, Trump, upgraded, urothelial, user, VAI, venture, warfarin, willfully
Removed:
acquire, antibody, Burst, Cambridge, Children, Coated, commenced, concept, Congestion, deteriorating, device, Dimetapp, encountered, family, Film, Flavor, Geno, Germano, Goldman, guideline, initially, initiative, Kendall, Korean, KPMG, LLP, men, Migraine, negligible, Norvasc, Notice, penalty, PM, Premarin, promise, proof, reimbursed, repurchase, restricted, Retirement, secured, Silver, smith, Specialist, streamline, surrender, thereunder, uptake, utilized, women
Filing tables
Filing exhibits
- 10-K Annual report
- 10.4 Form of Ackn Consent Summary of Key Terms for Stock Option Grants, Rsus & Tsrus
- 10.6 PFE Consolidated Supplemental Pension Plan for U.S. and Puerto Rico Employees
- 10.9 Amendment No 2 to the Pfizer Supplemental Savings Plan
- 10.26 Form of Special Performance Based Incentive Award Letter
- 10.27 Form of Special Performance Based Incentive Grant Letter
- 12 Computation of Ratio of Earnings to Fixed Charges
- 13 2017 Financial Report
- 21 Subsidiaries of the Company
- 23 Consent of KPMG, Independent Registered Public Accounting Firm
- 31.1 Certification by the Chief Executive Officer - 302
- 31.2 Certification by the Chief Financial Officer - 302
- 32.1 Certification by the Chief Executive Officer - 906
- 32.2 Certification by the Chief Financial Officer - 906
- Download Excel data file
- View Excel data file
Related press release
Associated PFE transcripts
PFE similar filings
Filing view
External links
EXHIBIT 32.2
Certification by the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002
Pursuant to 18 U.S.C. Section 1350, I, Frank A. D'Amelio, hereby certify that, to the best of my knowledge, the Annual Report on Form 10-K of Pfizer Inc. for the year ended December 31, 2017 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, and that the information contained in that Report fairly presents, in all material respects, the financial condition and results of operations of Pfizer Inc.
/s/ FRANK A. D'AMELIO | ||
Frank A. D'Amelio | ||
Executive Vice President, Business Operations and Chief Financial Officer | ||
February 22, 2018 |
This certification accompanies this Annual Report on Form 10-K pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.